New anti-cancer drugs: Effects of trifluridine and tipiracil (Lanceford) tablets on tumors

Trifluridine and tipiracil (Lonsurf) are an innovative combination of drugs designed to treat metastatic colorectal and gastric cancer. This drug uniquely combines two active ingredients: trifluridine and tipiracil, which work together to fight malignancy.

Trifluridine is a powerful nucleoside metabolism inhibitor that can penetrate deep into the core of cancer cells and destroy itskey process of DNA synthesis. Tipiracil cleverly blocks the activity of thymidine phosphorylase, an enzyme that is hyperactive in a variety of solid tumors and breaks down trifluridine. Through this mechanism, tipiracil actually enhances the concentration and action time of trifluridine in tumor tissues, thereby aggravating the destruction of cancer cells.

Trifluridine and tipiracil are not drugs that directly shrink tumors. Its main function is to prolong the patient's survival time and improve the quality of life by controlling and inhibiting the growth rate of tumors. When the drug enters the body, it will act precisely on cancer cells, interfering with theirDNA synthesis, thereby limiting further tumor expansion.

Although trifluridine and pyridine may not cause tumors to shrink immediately, continued use of this drug may have a gradual effect on tumor size. However, each patient's response is unique, so doctors consider the patient's specific condition, the characteristics of the tumor, and overall health when developing treatment plans.

At present, there is no clear conclusion on the safety and effectiveness of trifluridine and tipiracil in children. At the same time, women should use effective contraceptive measures during treatment and for six months thereafter. It is crucial to have a thorough and thorough discussion with your doctor before starting this medication.